Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Coronary Angioplasty Is a Valid Alternative for Left Main Coronary Artery Disease

Courtesy of Dr. Carlos Fava.

Severe left main coronary artery (LMCA) lesions have a bad prognosis in coronary disease. In that scenario, current guidelines recommend surgery as the treatment of choice. However, due to the current development of second-generation drug-eluting stents (DES) and greater operator expertise, left main coronary artery angioplasty appears as a valid alternative in various modern randomized studies.

La ATC es una alternativa válida en el TCI

In this case, 6 studies (EXCEL, NOBLE, LE MANS, PRE COMBAT, Boudriot, and SYNTAX) including 4700 total patients were analyzed.


Read also: Burnout Syndrome among Cardiologists”.


There were no significant differences in all-cause mortality at 30 days (0.61; 95% confidence interval [CI]: 0.27 to 1.36), 1 year (0.66; 95% CI: 0.42 to 1.04), and 3 years (1.04; 95% CI: 0.81 to 1.33). However, there was a trend towards lower mortality during the first year.

 

The risk of major adverse cardiac events (MACE) at 30 days and 1 year was similar for both strategies; however, in the long term, it was higher for patients who underwent angioplasty, due to higher revascularization rates between the first and third year.

 

Patients who underwent angioplasty experienced less events of stroke at 30 days and 1 year. No difference was observed beyond that period. Conversely, the risk of acute myocardial infarction (MI) was similar at 30 days, 1 year, 3 years, and 10 years.


Read also: Clinical and Economic Costs Compete in the De-Escalation of Antiplatelet Therapy”.


The composite outcome of death, stroke and MI was lower with angioplasty at 30 days (0.67; 95% CI: 0.49 to 0.92), but similar at 1 and 3 years.

 

Conclusion

No significant differences in all-cause mortality were observed between angioplasty and myocardial revascularization surgery (MRS) in the short and the long term. Angioplasty was associated with a reduction in the risk of major cardiovascular events in the short term in patients with left main coronary artery (LMCA) stenosis, as well as with increased rates of MACE in the long term.

 

Editorial Comment

This meta-analysis of modern randomized studies shows that LMCA angioplasty is safe and offers outcomes similar to those obtained with MRS, beyond its short-term benefits.

 

While, after a year, patients who underwent angioplasty experienced more MACE events, this is mainly due to a higher need for reintervention and is in no way related to hard events such as death or stroke.

 

These results will surely improve with new stents, more technology involvement in the assessment of stent implantation, and greater cumulative operator expertise.

 

Courtesy of Dr. Carlos Fava.

 

Original title: All-Cause Mortality and Major Cardiovascular Outcomes Comparing Percutaneous Coronary Angioplasty Versus Coronary Bypass Grafting in the Treatment of Unprotected Left Main Stenosis: A Meta-Analysis of Short-Term and Long-Term Randomized Trials.

Reference: Jari A. Laukkanen, et al. Open Heart BMJ 2017;4e000638.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...